Comparing Daratumumab injection in thigh vs. abdomen for plasma cell disorders
Treatments studied
Part of Cancer clinical trials.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma (newly diagnosed or relapsed) or AL amyloidosis
- You are scheduled to start a treatment that includes daratumumab
- You have not had daratumumab before, or it's been more than 6 months since your last dose
- You are 18 years or older
- You are in fairly good health (able to care for yourself and up and about more than half the day)
- You are willing to come for weekly visits for 9 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
This trial tests a new pump system (FreedomEDGE®) to give daratumumab as a shot under the skin instead of the usual manual injection. It's for people with multiple myeloma or light chain amyloidosis who are already having daratumumab injections once a month.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.